The most prevalent and bioactive cucurbitacin is Cucurbitacin B (CuB, CHO), which is a tetracyclic triterpene chiefly present in the Cucurbitaceae family. CuB has a wide spectrum of pharmacological properties namely antioxidant, anticancer, hepatoprotective, anti-inflammatory, antiviral, hypoglycaemic, insecticidal, and neuroprotective properties, owing to its ability to regulate several signaling pathways, including the Janus kinase/signal transducer and activator of transcription-3 (JAK/STAT3), AMP-activated protein kinase (AMPK), nuclear factor (NF)-κB, nuclear factor erythroid 2-related factor-2/antioxidant responsive element (Nrf2/ARE), phosphoinositide 3-kinase (PI3K)/Akt, mitogen-activated protein kinase (MAPK), Hippo-Yes-associated protein (YAP), focal adhesion kinase (FAK), cancerous inhibitor of protein phosphatase-2A/protein phosphatase-2A (CIP2A/PP2A), Wnt and Notch pathways. The present review highlights the medicinal attributes of Cucurbitacin B (CuB) with special emphasis on their signaling pathways to provide key evidence of its therapeutic utility in the near future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ptr.8454 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multifaceted Therapeutic Impacts of Cucurbitacin B: Recent Evidences From Preclinical Studies.
Phytother Res
February 2025
Department of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, India.
The most prevalent and bioactive cucurbitacin is Cucurbitacin B (CuB, CHO), which is a tetracyclic triterpene chiefly present in the Cucurbitaceae family. CuB has a wide spectrum of pharmacological properties namely antioxidant, anticancer, hepatoprotective, anti-inflammatory, antiviral, hypoglycaemic, insecticidal, and neuroprotective properties, owing to its ability to regulate several signaling pathways, including the Janus kinase/signal transducer and activator of transcription-3 (JAK/STAT3), AMP-activated protein kinase (AMPK), nuclear factor (NF)-κB, nuclear factor erythroid 2-related factor-2/antioxidant responsive element (Nrf2/ARE), phosphoinositide 3-kinase (PI3K)/Akt, mitogen-activated protein kinase (MAPK), Hippo-Yes-associated protein (YAP), focal adhesion kinase (FAK), cancerous inhibitor of protein phosphatase-2A/protein phosphatase-2A (CIP2A/PP2A), Wnt and Notch pathways. The present review highlights the medicinal attributes of Cucurbitacin B (CuB) with special emphasis on their signaling pathways to provide key evidence of its therapeutic utility in the near future.
View Article and Find Full Text PDFEfficacy assessment of glycyrrhetinic acid-modified liposomes loaded with doxorubicin hydrochloride and cucurbitine B for synergistic treatment of hepatocellular carcinoma.
Int J Pharm
February 2025
School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, China; Shenyang Key Laboratory of Targeted Delivery of Chinese medicine, Shenyang 110000, China. Electronic address:
Objective: Hepatocellular carcinoma (HCC) is characterized by a high incidence rate, aggressive invasion and metastasis, and a significant postoperative recurrence rate. Targeted therapy plays a crucial role in the precise treatment of HCC. Studies have demonstrated that Glycyrrhetinic acid (GA) specific receptors are overexpressed on the surface of HCC cells.
View Article and Find Full Text PDFTranscription Factor CmWRKY13 Regulates Cucurbitacin B Biosynthesis Leading to Bitterness in Oriental Melon Fruit ().
J Agric Food Chem
November 2024
College of Horticulture, Shenyang Agricultural University, Shenyang 110866, China.
Bitterness, caused by cucurbitacin B (CuB), is one of the important traits that affects melon fruit quality and consumer acceptance. Therefore, the detailed mechanism behind the regulation of CuB biosynthesis on melon fruit needs to be further explored. This study investigated CuB content and transcriptomes of "YMR" melon fruit treated by 5 and 20 mg L CPPU.
View Article and Find Full Text PDFMetabolic fate of the natural anticancer agent cucurbitacin B: an LC-MS/MS-enabled profiling of its major phase I and II conjugates in vivo.
Anal Bioanal Chem
December 2024
Center of Molecular Metabolism, Nanjing University of Science and Technology, 200 Xiaolingwei Street, Nanjing, 210094, China.
Article Synopsis
- Cucurbitacin B (CuB) is a natural compound known for its strong anticancer effects, but its effectiveness is limited due to poor absorption in the body when taken orally.
- Researchers studied how CuB is metabolized in rats after oral administration, identifying 13 metabolites, with one key variant, CuB-Cys, showing similar anti-cancer activity as CuB but with less toxicity toward normal cells.
- The study sheds light on CuB's metabolic pathways and suggests that using its metabolites, like CuB-Cys, could enhance its therapeutic effects while minimizing side effects in cancer treatment.
Cucurbitacins mitigate vascular neointimal hyperplasia by suppressing cyclin A2 expression and inhibiting VSMC proliferation.
Animal Model Exp Med
August 2024
Advanced Institute for Medical Sciences, Dalian Medical University, Dalian, China.
Background: Restenosis frequently occurs after percutaneous angioplasty in patients with vascular occlusion and seriously threatens their health. Substantial evidence has revealed that preventing vascular smooth muscle cell proliferation using a drug-eluting stent is an effective approach to improve restenosis. Cucurbitacins have been demonstrated to exert an anti-proliferation effect in various tumors and a hypotensive effect.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!